Research ArticleHIV

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals

See allHide authors and affiliations

Science Translational Medicine  03 Oct 2018:
Vol. 10, Issue 461, eaau4711
DOI: 10.1126/scitranslmed.aau4711

Gut check for a promising HIV treatment

Eradicating HIV in infected patients likely requires disrupting the reservoir of infected T cells in the gastrointestinal tract. One way to accomplish this is by targeting cells expressing the α4β7, which has been tested in SIV models and is an approved therapy for inflammatory bowel disease. Uzzan and colleagues studied a small cohort of HIV-infected individuals on antiretroviral therapy that began anti-α4β7 treatment for their mild inflammatory bowel disease. The investigators performed colonoscopies before and several months after the anti-integrin treatment, allowing them to assess lymphoid populations and HIV prevalence before and after treatment. They saw that treatment disrupted local lymphoid aggregates and also affected peripheral immune populations. As with non–HIV-infected IBD patients, treatment was well tolerated. Their results are sure to draw interest from scientists and clinicians who believe targeting this integrin could possibly help cure HIV.

View Full Text

Stay Connected to Science Translational Medicine